Key result
Abnormal glucose tolerance in dilated cardiomyopathy prevented pacing-induced increases in glucose uptake, instead increasing NEFA oxidation to 2.9 μmol/min/gO2 equivalents (p<0.05).
Why the study?
Does abnormal glucose tolerance reduce myocardial metabolic flexibility in patients with dilated cardiomyopathy?
Cross-Sectional (n=15)
Does abnormal glucose tolerance reduce myocardial metabolic flexibility in patients with dilated cardiomyopathy?
p-value: p=< 0.05
Abnormal glucose tolerance in patients with dilated cardiomyopathy exacerbates the resting metabolic shift from fat to carbohydrates and impairs myocardial metabolic flexibility during increased workload.
May impair metabolic flexibility in DCM with glucose intolerance; hypothesis-generating and leaves open prognostic or therapeutic implications.
Dilated cardiomyopathy (DCM) is characterized by a metabolic shift from fat to carbohydrates and failure to increase myocardial glucose uptake in response to workload increments. We verified whether this pattern is influenced by an abnormal glucose tolerance (AGT). In 10 patients with DCM, 5 with normal glucose tolerance (DCM-NGT) and 5 with AGT (DCM-AGT), and 5 non-DCM subjects with AGT (N-AGT), we measured coronary blood flow and arteriovenous differences of oxygen and metabolites during Rest, Pacing (at 130 b/min), and Recovery. Myocardial lactate exchange and oleate oxidation were also measured. At Rest, DCM patients showed a reduced nonesterified fatty acids (NEFA) myocardial uptake, while glucose utilization increased only in DCM-AGT. In response to Pacing, glucose uptake promptly rose in N-AGT (from 72 ± 21 to 234 ± 73 nmol/min/g, p < 0.05), did not change in DCM-AGT, and slowly increased in DCM-NGT. DCM-AGT sustained the extra workload by increasing NEFA oxidation (from 1.3 ± 0.2 to 2.9 ± 0.1 μmol/min/gO2 equivalents, p < 0.05), while DCM-NGT showed a delayed increase in glucose uptake. Substrate oxidation rates paralleled the metabolites data. The presence of AGT in patients with DCM exacerbates both the shift from fat to carbohydrates in resting myocardial metabolism and the reduced myocardial metabolic flexibility in response to an increased workload. This trial is registered with ClinicalTrial.gov NCT02440217.
No takes yet. Share an insight, caveat, or question.
Tricò et al. (2015) conducted a cross-sectional in Dilated cardiomyopathy with abnormal glucose tolerance (n=15). Abnormal glucose tolerance vs. Normal glucose tolerance was evaluated on Myocardial glucose uptake and substrate oxidation in response to pacing (p=< 0.05). Abnormal glucose tolerance in dilated cardiomyopathy prevented pacing-induced increases in glucose uptake, instead increasing NEFA oxidation to 2.9 μmol/min/gO2 equivalents (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: